DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell–mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patie...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood Adv
Κύριοι συγγραφείς: Wudhikarn, Kitsada, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Devlin, Sean M., Batlevi, Connie Lee, Shah, Gunjan L., Scordo, Michael, Palomba, Maria Lia, Dahi, Parastoo B., Sauter, Craig S., Santomasso, Bianca D., Mead, Elena, Perales, Miguel-Angel
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2020
Θέματα:
Clinical Trials and Observations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362382/
https://ncbi.nlm.nih.gov/pubmed/32614964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001972
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια